Novo’s (NOVOB DC) once-weekly Sogroya (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)

For Novo, label expansion of an already-marketed product is a different event from a first approval; the manufacturing, reimbursement and commercial infrastructure for Sogroya is in place, and the incremental question is the size and pricing of the idiopathic short stature population across European markets, where access will be settled country by country through HTA and payer negotiations rather than at the EMA level. The first-and-only framing matters for precedent: sole status in an indication has historically supported pricing leverage in orphan-adjacent endocrine niches until a competitor files. Worth noting that growth hormone for ISS has been a contested reimbursement category in several European systems, so national payer decisions are the real gating item. The follow-ons are the formal Commission decision, the national HTA sequence, and any read-across to competing weekly growth hormone programmes. As regulatory news of this kind goes, the CHMP stage rarely moves the stock sharply on its own; the pattern has been for the commercial and payer details to drive the sustained re-rating.